Literature DB >> 19621664

Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma.

Hye Jeong Choi1, Hong Jin Kim, Joon Hyuk Choi.   

Abstract

BACKGROUND/AIMS: The c-erbB-2 proto-oncogene is important for tumor invasiveness and metastases. Cyclooxygenase-2 (COX-2) plays an important role in carcinogenesis in several types of human cancer. The link between c-erbB-2 and COX-2 has been described in breast, colorectal, and prostate cancers. High levels of COX-2 have been detected in c-erbB-2-positive tumors. This observation suggests that c-erbB-2 mediates the induction of COX-2 gene transcription. In the present study, the expressions of c-erbB-2 and COX-2 in intrahepatic cholangiocarcinoma, their correlations with clinicopathologic parameters, and the relationship between their expressions were evaluated.
METHODOLOGY: Immunohistochemical staining for c-erbB-2 and COX-2 was performed in paraffin-embedded sections of fifty surgically obtained intrahepatic cholangiocarcinomas.
RESULTS: The overexpression of c-erbB-2 was observed in 72% (36/50) of specimens. In groups with lymph node metastasis, distant metastasis and high TNM stage showed significantly lower expression. No significant correlation was found between c-erbB-2 overexpression and age, sex, tumor size, gross type, histologic grade, vascular invasion, or perineural invasion. The overexpression of COX-2 was observed in 40% (20/50) of specimens. COX-2 expression was not correlated with clinicopathologic parameters, except gross subtype. A positive correlation between c-erbB-2 and COX-2 expression was observed (p<0.05).
CONCLUSIONS: These results suggest that the c-erbB-2 is frequently overexpressed in intrahepatic cholangiocarcinomas, and its expression might play a role in regulating COX-2 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19621664

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.

Authors:  Siobhan C McKay; Kristian Unger; Stephanos Pericleous; Gordon Stamp; Gerry Thomas; Robert R Hutchins; Duncan R C Spalding
Journal:  HPB (Oxford)       Date:  2011-03-10       Impact factor: 3.647

Review 2.  Hilar cholangiocarcinoma: pathology and tumor biology.

Authors:  Dong Kuang; Guo-Ping Wang
Journal:  Front Med China       Date:  2010-11-25

Review 3.  HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Authors:  Salvatore Galdy; Angela Lamarca; Mairéad G McNamara; Richard A Hubner; Chiara A Cella; Nicola Fazio; Juan W Valle
Journal:  Cancer Metastasis Rev       Date:  2017-03       Impact factor: 9.264

4.  Reappraisal of the therapeutic role of celecoxib in cholangiocarcinoma.

Authors:  Chun-Nan Yeh; Kun-Chun Chiang; Horng-Heng Juang; Jong-Hwei S Pang; Chung-Shan Yu; Kun-Ju Lin; Ta-Sen Yeh; Yi-Yin Jan
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.